Chongqing University of Arts and Sciences is a full-time general undergraduate college sponsored by Chongqing Municipal People's Government. The university is located in Yongchuan District, Chongqing City, with Honghe Campus and Xinghu Campus. The campus covers an area of 1,767 mu, with a total value of RMB 360 million of teaching and scientific research instruments and equipment.
The university has more than 1500 teaching and administrative staff, including nearly 600 senior professional titles, more than 370 doctoral teachers, more than 130 doctoral supervisors and master supervisors, and more than 300 external experts.
The university has 19 secondary colleges, 66 general undergraduate majors, and 3 master's degree programs in machinery, materials and chemical engineering. It has over 20,000 full-time undergraduates and postgraduates, including over 100 international students.
At present, the school has 75 national, provincial and ministerial-level talents including leading talents of the national "Ten Thousand Strong Plan", and has established one national expert service base, 16 provincial innovation teams, and 1 postdoctoral research workstation. \
The university is one of the six high-level new engineering construction universities (cultivation) in the city. The school currently has 7 provincial-level key disciplines during the "14th Five Year Plan", 2 disciplines namely chemistry and materials, science and engineering ranking in the top 1% of ESI's global rankings, 3 national research platforms such as the international scientific and technological cooperation base "micro-nano optoelectronic materials and devices", and 27 provincial platforms. In the past 5 years, the university has won 50 provincial and ministerial level scientific and technological achievement awards, including 8 first prizes for scientific and technological progress awarded by the Ministry of Education and provincial governments. The school has been granted more than 900 patents, and its two international first-class new drugs, i.e. PDE5 anti-inhibitor and PZ-1 tablet, an anti-cancer new drug, have been transformed with RMB 30 million and RMB 48 million respectively.